Category: Oncotarget

Oncotarget News

Oncotarget | A Novel Mechanism of Regulation of the Oncogenic Transcription Factor GLI3 by Toll-like Receptor Signaling

August 9, 2022

These results increase our understanding of the signaling molecules that can regulate GLI3 in a HH-independent manner.”BUFFALO, NY- August 9, 2022 – A new research paper was published in Oncotarget... read more

Oncotarget

Oncotarget | Chemoradiation Alters PD-L1, CD8+ TILs and Mucin in Rectal Cancer

August 2, 2022

In conclusion, our study provides further data on the immunologic impact of nCRT in rectal cancer.”BUFFALO, NY- August 2, 2022 – A new research paper was published in ... read more

Oncotarget

Oncotarget | CUDC907 Promotes Apoptosis of NF2 Schwannoma Cells

July 26, 2022

CUDC907 has cytotoxic activity in NF2 schwannoma models and primary VS cells and is a candidate for clinical trials.”BUFFALO, NY- July 26, 2022 – A new research paper was... read more

Oncotarget

Oncotarget | Predicting Cancer Immunotherapy Response From Gut Microbiomes Using Machine Learning Models

July 19, 2022

Findings demonstrate how machine learning models can reveal microbiome-immunotherapy interactions that may ultimately improve cancer patient outcomes.”BUFFALO, NY- July 19, 2022 – A new research paper was published in&... read more

Oncotarget

Behind the Study: Molecular Characterization of Lung Carcinomas Expressing KK-LC-1

July 11, 2022

Dr. Robert Hsu from the University of Southern California, Norris Comprehensive Cancer Center, describes a recent research paper he co-authored that was published by Oncotarget, entitled, “Molecular characterization of... read more

Oncotarget

Oncotarget | Role of germline variants in the metastasis of breast carcinomas

July 7, 2022

We found several gene candidates through which the host’s genetic makeup contributes to metastasis.”BUFFALO, NY- July 7, 2022 – A new research paper was published in Oncotarget on June... read more

Oncotarget

Oncotarget | Continuous Treatment With Abemaciclib Leads to Sustained and Efficient Inhibition of Breast Cancer Cell Proliferation

July 6, 2022

These preclinical results support the unique efficacy and safety profile of abemaciclib observed in clinical trials.”BUFFALO, NY- July 6, 2022 – Researchers from Eli Lilly and Company ... read more

Oncotarget

Oncotarget | New Oncology-Focused Papers Published in Volume 13

June 23, 2022

BUFFALO, NY- June 23, 2022 – At the start of 2022, Oncotarget began publishing research papers in a continuous publishing format in yearly volumes. As of June 23, 2022, Oncotarget has... read more

PRESS RELEASE: Impact Journals is sponsoring Team Open Access on June 25, 2022, in the annual cycling event to end cancer: The Ride for Roswell.

Oncotarget

Impact Journals Sponsors 2022 Ride For Roswell

June 14, 2022

Impact Journals is sponsoring Team Open Access on June 25, 2022, in the annual cycling event to end cancer: The Ride for Roswell.BUFFALO, NY- June 14, 2022 – The&... read more

Oncotarget

Behind the Study: IGF-pathway Biomarkers and Lung Cancer

June 14, 2022

Dr. Alexander Pohlman from Rush Medical College, Rush University Medical Center, Chicago, IL, describes a recent review published by Oncotarget that he co-authored entitled, “The role of IGF-pathway biomarkers in... read more